Speransa Therapeutics
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins (NCT05367843) | Speransa Therapeutics | 2022-06-20 |
Track Speransa Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.